دورية أكاديمية
Syndecan-3 enhances anabolic bone formation through WNT signaling.
| العنوان: | Syndecan-3 enhances anabolic bone formation through WNT signaling. |
|---|---|
| المؤلفون: | Johnson de Sousa Brito FM; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Butcher A; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Pisconti A; Department of Biochemistry, IIB, University of Liverpool, Liverpool, UK.; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA., Poulet B; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Prior A; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Charlesworth G; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Sperinck C; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Scotto di Mase M; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Liu K; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Bou-Gharios G; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Jurgen van 't Hof R; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK., Daroszewska A; Department of Musculoskeletal and Ageing Science (formerly Department of Musculoskeletal Biology), Institute of Life Course and Medical Sciences (formerly Institute of Ageing and Chronic Disease), University of Liverpool, Liverpool, UK.; Department of Clinical Biochemistry and Metabolic Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.; Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. |
| المصدر: | FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2021 Apr; Vol. 35 (4), pp. e21246. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : [Bethesda, Md.] : Hoboken, NJ : Federation of American Societies for Experimental Biology ; Wiley Original Publication: [Bethesda, Md.] : The Federation, [c1987- |
| مواضيع طبية MeSH: | Bone Development/*physiology , Syndecan-3/*metabolism , Wnt Signaling Pathway/*physiology, Animals ; Animals, Newborn ; Antibodies ; Cell Proliferation ; Fetal Development ; Male ; Mice ; Mice, Knockout ; Osteoblasts ; Osteoclasts ; Syndecan-3/genetics |
| مستخلص: | Osteoporosis is the most common age-related metabolic bone disorder, which is characterized by low bone mass and deterioration in bone architecture, with a propensity to fragility fractures. The best treatment for osteoporosis relies on stimulation of osteoblasts to form new bone and restore bone structure, however, anabolic therapeutics are few and their use is time restricted. Here, we report that Syndecan-3 increases new bone formation through enhancement of WNT signaling in osteoblasts. Young adult Sdc3 -/- mice have low bone volume, reduced bone formation, increased bone marrow adipose tissue, increased bone fragility, and a blunted anabolic bone formation response to mechanical loading. This premature osteoporosis-like phenotype of Sdc3 -/- mice is due to delayed osteoblast maturation and impaired osteoblast function, with contributing increased osteoclast-mediated bone resorption. Indeed, overexpressing Sdc3 in osteoblasts using the Col1a1 promoter rescues the low bone volume phenotype of the Sdc3 -/- mice, and also increases bone volume in WT mice. Mechanistically, SDC3 enhances canonical WNT signaling in osteoblasts through stabilization of Frizzled 1, making SDC3 an attractive target for novel bone anabolic drug development. (© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.) |
| References: | Osteoporos Int. 2006 Dec;17(12):1726-33. (PMID: 16983459) Skelet Muscle. 2016 Oct 4;6:34. (PMID: 27757223) Nat Med. 2012 Feb 19;18(3):405-12. (PMID: 22344299) PLoS One. 2010 May 18;5(5):e10692. (PMID: 20502692) Bioessays. 2000 Feb;22(2):138-47. (PMID: 10655033) Matrix Biol. 2006 Jan;25(1):27-39. (PMID: 16226436) Bone. 2009 May;44(5):785-94. (PMID: 19442624) Nature. 2018 May;557(7706):564-569. (PMID: 29769720) Development. 2008 Mar;135(6):1049-58. (PMID: 18256198) PLoS One. 2014 Jun 04;9(6):e98861. (PMID: 24897117) J Bone Miner Metab. 2005;23(3):191-9. (PMID: 15838620) Bone. 2015 Jan;70:28-36. (PMID: 25138551) Int J Mol Med. 2007 Mar;19(3):529-33. (PMID: 17273804) Methods Mol Biol. 2012;816:177-86. (PMID: 22130929) Endocrinology. 2009 Jan;150(1):5-13. (PMID: 18772231) Cell Death Dis. 2017 Jun 29;8(6):e2902. (PMID: 28661485) J Bone Miner Res. 2013 Jan;28(1):2-17. (PMID: 23197339) Bone. 2005 Dec;37(6):810-8. (PMID: 16198164) Bone. 2017 Jun;99:69-79. (PMID: 28366796) Methods Mol Biol. 2012;816:461-76. (PMID: 22130944) J Biol Chem. 1994 Apr 29;269(17):12999-3004. (PMID: 8175719) JBMR Plus. 2018 May;2(3):164-173. (PMID: 30009278) Development. 2007 Jun;134(11):2159-69. (PMID: 17507416) Exp Cell Res. 1996 Nov 25;229(1):126-36. (PMID: 8940256) J Cell Biochem. 2011 Dec;112(12):3491-501. (PMID: 21793042) Nat Genet. 2000 Jul;25(3):329-32. (PMID: 10888884) Eur J Endocrinol. 2018 Feb;178(2):R33-R44. (PMID: 29113980) J Orthop Res. 1996 May;14(3):403-12. (PMID: 8676253) Cold Spring Harb Perspect Biol. 2012 Oct 01;4(10):. (PMID: 22935904) Elife. 2018 Feb 06;7:. (PMID: 29405118) Mol Cell Neurosci. 2002 Sep;21(1):158-72. (PMID: 12359158) Dev Dyn. 2004 Mar;229(3):607-17. (PMID: 14991716) Nat Rev Dis Primers. 2016 Sep 29;2:16069. (PMID: 27681935) Nat Med. 2013 Feb;19(2):179-92. (PMID: 23389618) FEBS J. 2017 Jan;284(1):27-41. (PMID: 27790852) Dev Dyn. 2002 Jun;224(2):245-51. (PMID: 12112477) Exp Cell Res. 2011 Apr 1;317(6):745-56. (PMID: 21211534) Dev Dyn. 1995 Jun;203(2):152-62. (PMID: 7544653) Stem Cells Dev. 2016 Apr 1;25(7):522-9. (PMID: 26847503) J Biol Chem. 2015 Mar 13;290(11):6789-98. (PMID: 25605717) Mol Cell Biol. 2006 Apr;26(8):2955-64. (PMID: 16581771) J Biol Chem. 2005 May 13;280(19):19185-95. (PMID: 15760903) Nature. 2018 May;557(7706):495-496. (PMID: 29777190) J Cell Physiol. 2006 Jul;208(1):77-86. (PMID: 16575901) J Biol Chem. 2008 Feb 29;283(9):5866-75. (PMID: 18089564) J Cell Biochem. 2008 May 15;104(2):568-79. (PMID: 18186078) BMC Cell Biol. 2015 Mar 13;16:9. (PMID: 25887471) Genes Dev. 2015 Jul 15;29(14):1463-86. (PMID: 26220993) FASEB J. 2021 Apr;35(4):e21246. (PMID: 33769615) J Bone Miner Res. 2016 Jan;31(1):65-75. (PMID: 26189772) Bone. 2013 Oct;56(2):234-41. (PMID: 23806799) Nature. 2019 Mar;567(7747):178-179. (PMID: 30850738) J Histochem Cytochem. 2015 Jul;63(7):465-80. (PMID: 25910817) J Cell Biol. 2010 Aug 9;190(3):427-41. (PMID: 20696709) Int J Exp Pathol. 2015 Feb;96(1):1-10. (PMID: 25546317) J Cell Biol. 1998 Nov 16;143(4):1113-28. (PMID: 9817766) Cell Death Dis. 2018 Nov 2;9(11):1119. (PMID: 30389911) Dev Biol. 1995 Apr;168(2):438-51. (PMID: 7729580) Dev Cell. 2011 Mar 15;20(3):303-14. (PMID: 21397842) Calcif Tissue Int. 2008 Mar;82(3):191-201. (PMID: 18259679) Nature. 2019 Mar;567(7747):234-238. (PMID: 30814736) FEBS Lett. 2008 Mar 5;582(5):643-50. (PMID: 18242177) |
| معلومات مُعتمدة: | MR/P020941/1 United Kingdom MRC_ Medical Research Council; MR/R002819/1 RCUK | Medical Research Council (MRC) |
| فهرسة مساهمة: | Keywords: Syndecan-3; WNT; bone; frizzled; osteoblast |
| المشرفين على المادة: | 0 (Antibodies) 0 (Sdc3 protein, mouse) 0 (Syndecan-3) |
| تواريخ الأحداث: | Date Created: 20210326 Date Completed: 20210719 Latest Revision: 20220216 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8251628 |
| DOI: | 10.1096/fj.202002024R |
| PMID: | 33769615 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1530-6860 |
|---|---|
| DOI: | 10.1096/fj.202002024R |